Hadlima is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis and active psoriatic arthritis. Hadlima is also known by its drug name, adalimumab-bwwd.
Hadlima is a biologic. It is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Hadlima is believed to work by blocking chemical signals in the body that can lead to inflammation, irritation, and itching. Hadlima is biologically similar to the FDA-approved drug Humira (adalimumab).
How do I take it?
Prescribing information states that Hadlima is given as a subcutaneous injection every other week. It should be administered according to the frequency specified by the physician.
Hadlima is available only as a single-dose prefilled autoinjector or as a single-dose prefilled glass syringe.
The FDA-approved label for Hadlima lists common side effects that include infections, injection site reactions, headache, and rash.
Serious side effects listed for Hadlima include invasive fungal infections, tuberculosis, severe allergic reactions, very low blood cell counts, heart failure, and certain types of cancer such as lymphoma.
For more details about this treatment, visit:
Humira vs. Hadlima — RxList
Hadlima — RheumInfo